Arch Point Investors Regenxbio Inc. Transaction History

Arch Point Investors

$228 Million
Q1 2024

A detailed history of Arch Point Investors transactions in Regenxbio Inc. stock. As of the latest transaction made, Arch Point Investors holds 224,278 shares of RGNX stock, worth $2.38 Million. This represents 2.07% of its overall portfolio holdings.

Number of Shares

224,278

Previous 224,278 -0.0%

Holding current value

$2.38 Million

Previous $4.03 Million 17.39%

% of portfolio

2.07%

Previous 1.73%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$20.4 - $24.73 $578,340 - $701,095	-28,350 Reduced 11.22%	224,278 $5.09 Million
Q3 2022 Nov 14, 2022	SELL	$22.29 - $35.04 $12,326 - $19,377	-553 Reduced 0.22%	252,628 $6.68 Million
Q2 2022 Aug 12, 2022	SELL	$19.35 - $35.04 $970,866 - $1.76 Million	-50,174 Reduced 16.54%	253,181 $6.25 Million
Q4 2021 Feb 11, 2022	BUY	$30.19 - $40.28 $181,140 - $241,680	6,000 Added 2.02%	303,355 $9.92 Million
Q3 2021 Nov 12, 2021	BUY	$29.09 - $45.68 $297,270 - $466,803	10,219 Added 3.56%	297,355 $12.5 Million

Q2 2021 Aug 13, 2021	BUY	$32.46 - $40.48 $1.17 Million - $1.46 Million	36,078 Added 14.37%	287,136 $11.2 Million
Q1 2021 May 13, 2021	SELL	$33.61 - $49.95 $1.62 Million - $2.41 Million	-48,189 Reduced 16.1%	251,058 $8.56 Million
Q4 2020 Feb 12, 2021	BUY	$26.52 - $49.35 $22,356 - $41,602	843 Added 0.28%	299,247 $13.6 Million
Q3 2020 Nov 13, 2020	SELL	$27.01 - $40.26 $69,064 - $102,944	-2,557 Reduced 0.85%	298,404 $8.21 Million
Q2 2020 Jul 31, 2020	BUY	$27.75 - $43.44 $41,625 - $65,160	1,500 Added 0.5%	300,961 $11.1 Million
Q1 2020 May 13, 2020	SELL	$21.5 - $54.2 $10,535 - $26,558	-490 Reduced 0.16%	299,461 $9.7 Million
Q4 2019 Feb 12, 2020	BUY	$34.54 - $44.87 $16,924 - $21,986	490 Added 0.16%	299,951 $12.3 Million
Q3 2019 Nov 13, 2019	BUY	$31.84 - $50.88 $1.66 Million - $2.65 Million	52,124 Added 21.07%	299,461 $10.7 Million
Q2 2019 Jul 26, 2019	BUY	$42.0 - $59.29 $277,200 - $391,314	6,600 Added 2.74%	247,337 $12.7 Million
Q1 2019 May 10, 2019	BUY	$40.82 - $62.45 $738,433 - $1.13 Million	18,090 Added 8.12%	240,737 $13.8 Million
Q4 2018 Feb 14, 2019	SELL	$39.11 - $75.15 $60,229 - $115,731	-1,540 Reduced 0.69%	222,647 $9.34 Million
Q3 2018 Oct 24, 2018	BUY	$65.0 - $82.15 $1.2 Million - $1.52 Million	18,473 Added 8.98%	224,187 $16.9 Million
Q2 2018 Aug 14, 2018	BUY	$27.2 - $74.35 $89,488 - $244,611	3,290 Added 1.63%	205,714 $14.8 Million
Q1 2018 May 15, 2018	BUY	$24.05 - $37.5 $382,058 - $595,725	15,886 Added 8.52%	202,424 $6.04 Million
Q4 2017 Feb 14, 2018	SELL	$26.0 - $34.6 $13,000 - $17,300	-500 Reduced 0.27%	186,538 $6.2 Million
Q3 2017 Nov 14, 2017	BUY	$18.0 - $32.95 $3.37 Million - $6.16 Million	187,038	187,038 $6.16 Million

Others Institutions Holding RGNX

# of Institutions

193

Shares Held

42.1M

Call Options Held

80.6K

Put Options Held

55.2K

View Full List

About REGENXBIO Inc.

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $460M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

More about RGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Arch Point Investors, based on Form 13F filings with the SEC.

News

Stay updated on Arch Point Investors with notifications on news.

Account

Arch Point Investors Regenxbio Inc. Transaction History